Exploratory analysis of serum and urine biomarkers associated with nausea and vomittings induced by highly emetogenic chemotherapy (Biomarker study of TRIPLE)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006143

Enrollment

Registered

2011-08-10

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic tumor

Interventions

granisetron1mg+dexamethasone(d1-4)+aprepitant(d1-3) palonosetron0.75mg+dexamethasone(d1-4)+aprepitant(d1-3)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients who registered the TRIPLE study. 2. patients treated at division of thoracic oncology, Shizuoka Cancer Center. 3. all subjects must be able to provide informed,written consent prio to entry.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
Association between serum and urine biomarkers and chemotherapy induced nausea and vomittings.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026